Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Scott Moomaw sold 8,863 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $252,418.24. Following the transaction, the insider directly owned 181,487 shares of the company’s stock, valued at approximately $5,168,749.76. This represents a 4.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Liquidia Stock Performance
Shares of Liquidia stock traded down $0.86 during trading on Tuesday, reaching $26.81. The company’s stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. Liquidia Corporation has a one year low of $21.94 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a market cap of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61. The business’s fifty day moving average price is $63.40 and its 200-day moving average price is $61.76.
Liquidia (NASDAQ:LQDA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the firm posted ($0.49) EPS. Liquidia’s revenue for the quarter was up 1842.1% on a year-over-year basis. As a group, equities research analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.
Analysts Set New Price Targets
Get Our Latest Analysis on LQDA
Key Liquidia News
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
- Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
- Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
- Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
- Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
- Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week
Institutional Investors Weigh In On Liquidia
Several hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd acquired a new stake in Liquidia during the second quarter worth about $335,000. Arizona State Retirement System increased its stake in Liquidia by 5.4% during the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after acquiring an additional 900 shares during the period. Nykredit A S bought a new position in Liquidia during the second quarter valued at about $177,000. Corient Private Wealth LP acquired a new position in Liquidia in the 2nd quarter valued at approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Liquidia during the second quarter valued at approximately $1,236,000. Institutional investors own 64.54% of the company’s stock.
About Liquidia
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.
Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
